Parse Biosciences and Graph Therapeutics announced a strategic partnership to generate a large, multi‑context immune perturbation atlas by profiling hundreds of millions of cells from patients with immune diseases. The collaboration will combine Graph’s lab‑in‑the‑loop patient‑derived disease models and active learning to select perturbations with Parse’s GigaLab/Evercode single‑cell platform to create datasets intended to derisk target selection and accelerate AI‑first drug discovery. The effort aims to resolve context‑specific immune responses that often cause late‑stage failures in immunotherapy development.